Triasima Portfolio Management inc. Acquires 18,360 Shares of Fresenius Medical Care AG (NYSE:FMS)

Triasima Portfolio Management inc. raised its stake in shares of Fresenius Medical Care AG (NYSE:FMS) by 27.4% during the 2nd quarter, Holdings Channel.com reports. The fund owned 85,430 shares of the company’s stock after purchasing an additional 18,360 shares during the quarter. Triasima Portfolio Management inc.’s holdings in Fresenius Medical Care were worth $1,631,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in the stock. Assetmark Inc. raised its holdings in shares of Fresenius Medical Care by 169.9% during the fourth quarter. Assetmark Inc. now owns 4,178 shares of the company’s stock valued at $87,000 after purchasing an additional 2,630 shares during the last quarter. GAMMA Investing LLC grew its position in Fresenius Medical Care by 21.8% in the 1st quarter. GAMMA Investing LLC now owns 4,230 shares of the company’s stock worth $82,000 after purchasing an additional 758 shares during the period. ORG Partners LLC purchased a new stake in Fresenius Medical Care during the 1st quarter valued at $110,000. SageView Advisory Group LLC bought a new position in shares of Fresenius Medical Care during the 1st quarter valued at $127,000. Finally, Signaturefd LLC boosted its stake in shares of Fresenius Medical Care by 8.4% in the 2nd quarter. Signaturefd LLC now owns 8,713 shares of the company’s stock worth $166,000 after buying an additional 672 shares during the last quarter. Hedge funds and other institutional investors own 8.25% of the company’s stock.

Fresenius Medical Care Stock Performance

Fresenius Medical Care stock traded down $0.15 during trading on Friday, reaching $19.68. The company had a trading volume of 179,354 shares, compared to its average volume of 386,998. The firm has a market capitalization of $11.55 billion, a price-to-earnings ratio of 22.11, a price-to-earnings-growth ratio of 1.03 and a beta of 0.90. The company has a current ratio of 1.46, a quick ratio of 1.09 and a debt-to-equity ratio of 0.45. The firm’s 50-day simple moving average is $19.33 and its 200 day simple moving average is $19.85. Fresenius Medical Care AG has a 52 week low of $16.37 and a 52 week high of $23.29.

Fresenius Medical Care (NYSE:FMS) last issued its quarterly earnings results on Tuesday, July 30th. The company reported $0.38 EPS for the quarter, hitting analysts’ consensus estimates of $0.38. Fresenius Medical Care had a return on equity of 5.48% and a net margin of 2.72%. The business had revenue of $5.13 billion during the quarter, compared to analysts’ expectations of $5.28 billion. Sell-side analysts forecast that Fresenius Medical Care AG will post 1.51 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently commented on FMS. Truist Financial reduced their price objective on Fresenius Medical Care from $24.00 to $22.00 and set a “hold” rating for the company in a research report on Wednesday, July 31st. StockNews.com started coverage on shares of Fresenius Medical Care in a research note on Friday. They issued a “strong-buy” rating on the stock. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $22.00.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.